Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Cadrenal Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsJun-30-23Mar-31-23Jun-30-22
   10-Q10-Q10-Q
Operating expenses:     
General and administrative expenses  0.81.00.3
Research and development expenses  0.23.20.2
Depreciation expense  0.00.0 
    Total operating expenses  1.09.40.5
    Loss from operations  -1.0-4.2-0.5
   
Other expense:     
Interest and dividend income  0.0  
Interest expense   0.00.0
Interest expense, amortization of debt discount   0.00.0
Change in fair value of derivative liabilities   0.20.0
Loss on extinguishment of debt   0.7 
Total other (income) expenses  0.0 0.0
   
    Net loss and comprehensive loss     
Net loss per common share, basic and diluted (in Dollars per share)  ($0.09)($0.48)($0.07)
   
Weighted average number of common shares used in computing net loss per common share, basic and diluted  11.710.87.7

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy